Dr. Tadataka Yamada Joins Frazier Healthcare

SEATTLE--(BUSINESS WIRE)-- Frazier Healthcare, a leading provider of growth equity and venture capital to high growth and emerging healthcare companies, announced today that Dr. Tadataka (Tachi) Yamada has joined the firm as a Senior Executive in Residence. At Frazier Healthcare, Dr. Yamada will work with both the growth equity and venture capital teams in pursuing opportunities to launch and grow game-changing healthcare companies both in the U.S. and in emerging markets. Dr. Yamada was most recently the President of the Global Health Program for the Bill & Melinda Gates Foundation, where he led the foundation’s efforts to develop and deliver life-saving therapies in the developing world. Prior to the Gates Foundation, Dr. Yamada served as Chairman of R&D at GlaxoSmithKline, where he oversaw worldwide pharmaceutical research and development; he also served as a member of the GSK Board of Directors.

“I’m very excited to join Frazier Healthcare in this new role,” stated Dr. Yamada. “Frazier has a tremendous track record of successfully partnering with entrepreneurs to build healthcare companies that address major health needs, illustrated most recently in Calistoga Pharmaceuticals, Marcadia Biotech, and Bravo Health. With its focus on healthcare and unique combination growth equity and venture capital strategies, I feel that Frazier Healthcare is an outstanding platform for me to build entrepreneurial healthcare organizations.”

“We are thrilled to have Tachi join our already strong team,” said Alan Frazier, Managing Partner of Frazier Healthcare. “His unparalleled global reach and wide-ranging expertise in healthcare will be major assets as we look to identify and create companies that build value for our investors by delivering therapies and services that improve patient outcomes and add efficiencies to healthcare delivery. In addition, his leadership and proficiency in growing and managing top-notch organizations will be critical in guiding our portfolio of high-growth and emerging companies.”

“Leveraging Tachi’s experiences as head of R&D of a major pharmaceutical company and as leader of a highly-regarded global organization such as the Gates Foundation will provide a major advantage in identifying and developing new, innovative ventures,” said Jamie Topper, General Partner with Frazier Healthcare. “Combining Tachi’s unique capabilities with our distinctive track-record of growth equity and venture capital investing is a strong formula for success.”

Dr. Yamada will split his time between his role with Frazier Healthcare and as a member of the board and an advisor to the CEO of Takeda Pharmaceuticals.

About Frazier Healthcare

Founded in 1991, Frazier Healthcare is a leading provider of growth equity and venture capital to high growth and emerging health care service, biopharma and medical device companies. With over $1.8 billion under management across seven funds, Frazier Healthcare has invested in over 100 companies across the entire developmental spectrum. From seed stage venture investments to leveraged recapitalizations of cash generating companies, Frazier Healthcare has established itself among entrepreneurs and seasoned executives as a preferred partner to help create and grow successful health care companies.

For more, please visit Frazier Healthcare’s website at www.frazierhealthcare.com



CONTACT:

Frazier Healthcare
James Topper, 650-325-5156
General Partner
[email protected]

KEYWORDS:   United States  North America  Washington

INDUSTRY KEYWORDS:   Health  Biotechnology  Hospitals  Medical Devices  Pharmaceutical  Professional Services  Banking  Finance  Research  Other Science  Science  General Health

MEDIA:

Logo
 Logo

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.